Table 2.
Non-infectious complications.
| No. |
% of cohort (n = 623) |
Chapel et al. (8) (n = 334) |
Quinti et al. (20) (n = 224) |
Wehr et al. (21) (n = 303) |
Farmer et al. (24) (n = 205) |
|
|---|---|---|---|---|---|---|
| Infection only | 199 | 31.9 | 26% | NR | NR | NR |
| Non-infectious complication | 424 | 68.1 | 74% | NR | NR | NR |
| Autoimmunity | 207 | 33.2 | NR | 25.9% | 20.3% | NR |
| Chronic lung disease | 189 | 30.3 | NR | 46.4% | NR | NR |
| Lymphoid hyperplasia/splenomegaly | 130 | 20.9 | 30% | 26.4%** | 40.5%** | 25.9%** |
| Gastrointestinal disease | 108 | 17.3 | 9% | 22.4%*** | NR | 21.5% |
| Liver disease | 79 | 12.7 | 9%* | NR | NR | 9.3% |
| Granulomas | 58 | 9.3 | 8% | NR | 11.6% | 20% |
| Lymphoma | 42 | 6.7 | 3% | 1.8% | NR | 5% |
| Other malignancies | 40 | 6.4 | 3% | 4.5% | NR | 22%**** |
*
Categorized as hepatomegaly in the original study.
**
categorized as splenomegaly in the original studies.
***
categorized as chronic diarrhea in the original study.
****
categorized as solid organ malignancy in the original study. NR, Not reported.